Dipeptidyl peptidase-4 (DPP-4) inhibitors are a class of oral hypoglycemics that block the enzyme DPP-4, which is involved in the inactivation of incretin hormones. These drugs help in the management of type 2 diabetes mellitus by increasing insulin release and decreasing glucagon levels in the circulation. Commonly known DPP-4 inhibitors include sitagliptin, saxagliptin, and linagliptin.
